Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer


Submitted: 19 March 2018
Accepted: 31 May 2018
Published: 4 June 2018
Abstract Views: 857
PDF: 390
HTML: 93
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Amin Abbasi Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran, Islamic Republic of.
  • Sahar Heydari Department of genetic, Biology Research Center, Zanjan Branch, Islamic Azad University, Zanjan, Iran, Islamic Republic of.
As gastric cancer has no exclusive signals in its initial phases, it is usually diagnosed in advanced phases. Although many researches have been conducted on methylation and diagnosis of cancer’s markers, the methylation and expression of Reprimo gene and its correlation with gastric cancer has not been thoroughly studied. Methylation of Reprimo promoter is a repetitive procedure exclusive to cancer which nullifies its expression and performance. The present research seeks to study the expression and methylation of Reprimo among people suffering with gastric cancer so that it may be used as a biomarker for early diagnosis. Fifty blood samples taken from healthy people (normal samples) and 50 blood samples obtained from gastric cancer patients were analyzed using Real-Time PCR. The methylation status of the promoter of Reprimo was studied using Methylation Specific PCR technique in normal samples and in gastric cancer Iranian patients. We observed reduction in expression rate of Reprimo in the blood samples of patients suffering with gastric cancer in comparison to normal blood samples. A significant correlation was also observed between the expression rate of this gene, age and methylation of its promoter among patients suffering with gastric cancer and various analysis points to a correlation between reduced expressions of Reprimo gene in gastric cancer patients. In conclusion, reduced expression of Reprimo gene and greater levels of methylation of its promoter seems to be promising biomarkers for early diagnosis of gastric cancer.

Abbasi, A., & Heydari, S. (2018). Studying the expression rate and methylation of Reprimo gene in the blood of patients suffering from gastric cancer. European Journal of Translational Myology, 28(2). https://doi.org/10.4081/ejtm.2018.7423

Downloads

Download data is not yet available.

Citations